Next‐generation sequencing of PTEN mutations for monitoring minimal residual disease in T‐cell acute lymphoblastic leukemia. Issue 1 (1st October 2019)

• Record Type: Journal Article
• Authors: Germano, Giuseppe; Valsecchi, Maria Grazia; Buldini, Barbara; Cazzaniga, Giovanni; Zanon, Carlo; Silvestri, Daniela; te Kronnie, Geertruij; Basso, Giuseppe; Paganin, Maddalena
• Is Part Of: Pediatric blood & cancer. Volume 67:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-10-01
• Subjects: MRD -- NGS -- PTEN -- T‐ALL; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28025
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Minimal residual disease (MRD) analysis has become a powerful indicator to refine therapy in acute lymphoblastic leukemia (ALL). Here, we present an MRD detection based on the next‐generation sequencing of PTEN exon 7 mutations (NGS‐PTEN) in 30 pediatric T‐cell ALL patients. By comparing the NGS‐PTEN results with current quantitative PCR of antigen receptor gene rearrangements (qPCR‐Ig/TR), an overall concordance of 80% was found between the two methods. However, the NGS‐PTEN qualified a lower number of high‐risk patients than qPCR‐Ig/TR. These findings suggest that NGS‐PTEN is a promising tool that could potentially be used to support current MRD methodologies for T‐ALL patients.